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the probabilities of adverse events related to proton therapy; the rates of death; the efficacy of proton therapy versus conventional radiation (expressed as relative risk, RR); and health utility reductions associated with adverse events.
Study designs and other criteria for inclusion in the review
The authors identified primary studies used as the source of clinical data from a systematic review of the literature, but details of the review were not reported. Little information on the design, sample size and other characteristics of these studies was provided. Many studies were performed in the Swedish context.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 50 primary studies provided the clinical data.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
For BC patients, in comparison with the general population, the increased risk of ischaemic heart disease was 43%, the increased risk of other cardiovascular disease was 27%, and the annual risk of pneumonitis was 14%. The utility reduction associated with ischaemic heart disease was 10%, and 20% for other cardiovascular disease. The RR of ischaemic heart disease, other cardiovascular disease or pneumonitis with proton therapy versus conventional radiation was 0.24.
For PC patients, the rate of PC death for 15 years was 2.5%. The annual probability of mild gastrointestinal adverse events was 14%, the annual probability of severe gastrointestinal adverse events was 4%, the annual probability of mild urogenital adverse events was 9%, and the annual probability of severe urogenital adverse events was 0.5%. The RR of PC-related death (proton therapy versus conventional therapy) was 0.8, while the RR of adverse events was 0.6. The utility reduction associated with adverse events was 7%.
The mortality rate associated with HNC was 16% for 8 years and the RR of death (proton therapy versus conventional therapy) was 0.76.
For children with MB, the rate of death due to subsequent cancer was 0.11% and the rate of death due to cardiac disease and other deaths was 0.056%. The probability of hearing loss was 13%, the IQ loss was 4.25 points, the probability of hypothyroidism was 33%, the probability of growth hormone deficiency was 18.7%, and the probability of osteoporosis was 2.4%. The rate of nonfatal cancers was 0.32%. The RR (proton therapy versus conventional therapy) was 0.48 for death due to subsequent cancer, 0.77 for death due to cardiac disease and other deaths, and 0.12 for other events. The utility reduction was 18% for hearing loss, 10% during one year for hypothyroidism, 20% for growth hormone deficiency, and 2% for osteoporosis.
Measure of benefits used in the economic analysis
The summary benefit measure used was the total number of quality-adjusted life-years (QALYs) associated with proton therapy in comparison with conventional treatment. The QALYs were estimated by combining, in the decision model, survival data and utility weights obtained from the literature. An annual discount rate of 3% was applied.
Direct costs
The perspective used in the analysis was not explicitly stated, but the main costs were those associated with proton therapy and conventional treatment, and the treatment of adverse events associated with therapy. With respect to radiotherapy, the three main cost categories considered were operation costs, capital costs, and travel and/or hotel costs. Some details on the calculation of the radiotherapy costs were reported, but information on resource consumption and unit costs associated with side effects was not given. The proportion of patients requiring travel and transportation costs was based on authors' assumptions. Most estimates came from published studies. Swedish sources were used for the unit costs. Discounting was relevant as long-term costs were evaluated, and an annual rate of 3% was applied. The price year was 2002, and the cost estimates for previous years were updated to 2002 values using the Swedish Consumer Price Index.
Statistical analysis of costs
Statistical analyses of the costs were not carried out.
Indirect Costs
The indirect costs were not considered.
Currency
Euros (EUR). The exchange rate from Swedish kroners (SEK) was EUR 1 = SEK 9.2.
Sensitivity analysis
Incremental cost-utility ratios were calculated to combine the costs and QALYs of proton therapy versus conventional therapy.
The incremental cost per QALY was EUR 34,290 for BC, EUR 26,776 for PC and EUR 3,811 for HNC. The incremental analysis revealed that proton radiation dominated conventional treatment for patients with MB.
Assuming a facility treated 300 patients with BC (population at high-risk of cardiac disease), 300 patients with PC, 300 patients with HNC and 25 cases of MB every year, the incremental cost per QALY gained per average patient with proton therapy in comparison with conventional radiotherapy was EUR 10,130.
The sensitivity analysis suggested that the cost-utility estimates were sensitive to variations in probability and cost estimates, given the great uncertainty surrounding some model inputs. However, proton therapy for MB was always a dominant strategy, regardless of variations in clinical estimates. The risk of cardiac disease in BC patients and the effect of proton therapy on PC patients and HNC patients were the most influential model inputs. If the value of a QALY gained was EUR 55,000 (the threshold for cost-effectiveness adopted in Sweden), the total yearly net benefit in Sweden of using proton therapy instead of standard therapy would be about EUR 20.8 million.
